Today, the first domestically developed IL-4R alpha antibody drug, Kangyueda (Sipuximab Injection), was prescribed for the first time in Shanghai at Huashan Hospital affiliated with Fudan University, marking the beginning of a new era in the treatment of moderate to severe atopic dermatitis with innovative Chinese new drugs. Professor Xu Jinhua from Huashan Hospital affiliated with Fudan University, who issued the first prescription, stated that atopic dermatitis is a chronic, inflammatory, and recurrent disease. Patients with the disease mainly present with stubborn skin lesions and itching, which seriously affects their work and life. The incidence rate of atopic dermatitis in Shanghai is relatively high. Because Shanghai is located at the junction of warm and hot areas, with distinct seasons, patients will get worse in the changing seasons, especially in rainy days. The Sprucubizumab prescribed this time is an antibody drug targeting the interleukin-4 receptor alpha subunit (IL-4R α), which can block the key cytokines involved in the onset of atopic dermatitis, thereby inhibiting disease progression and relieving the condition. The launch of Sipuximab monoclonal antibody fills the gap in domestic atopic dermatitis biologics and brings new choices for atopic dermatitis patients. The disease burden of atopic dermatitis ranks first among non fatal skin diseases. The data shows that the incidence rate of atopic dermatitis in China is increasing year by year, involving people of all ages. The proportion of moderate and severe patients is nearly 30%. It is estimated that there will be about 20.9 million patients with moderate and severe atopic dermatitis by 2025. In addition, as a chronic disease, atopic dermatitis occurs young and can last for decades. Some patients were diagnosed for the first time before the age of 20, and the course of moderate to severe atopic dermatitis in adult patients can even last for 25-30 years. The characteristic of atopic dermatitis being prone to recurrence causes patients to experience alternating periods of acute exacerbation and relative rest after treatment, with 50% of the time the condition worsens each year. In the field of disease treatment, there is a recognized EASI scoring system. For example, EASI-75 indicates a 75% improvement in the original eczema area and severity after medication use. Clinical data shows that after 52 weeks of monotherapy, the EASI-75 response rate reached 92.5%, and the EASI-90 response rate reached 77.1%. Kangyueda was approved for market by the National Medical Products Administration on September 12, 2024. With the implementation of the first prescription, Kangyueda will gradually enter clinical applications in various places. Experts in multiple cities such as Beijing, Shanghai, Guangzhou, and Chengdu have issued the first national and local prescriptions. (New Society)